CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
27 hedge funds and large institutions have $2.41M invested in CASI Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
8% more funds holding
Funds holding: 25 → 27 (+2)
0.01% less ownership
Funds ownership: 0.39% → 0.38% (-0.01%)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
27% less capital invested
Capital invested by funds: $3.33M → $2.41M (-$914K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$22K |
| 2 |
BlackRock
New York
|
+$19.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.71K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
+$1.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$62K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$39K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$15.5K |
| 4 |
Renaissance Technologies
New York
|
-$6.94K |
| 5 |
WSCM
Wellington Shields Capital Management
New York
|
-$2.53K |
CASI Hedge Fund Activity: Q2 2017 in Review
27 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2017, worth a combined $2.41M — down 27% from $3.33M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CASI positions and 2 closed out — a net gain of 2 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $22K. The largest seller was Vanguard Group, cutting an estimated $62K.
- 27 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2017, up from 25 in Q1 2017.
- Funds reported $2.41M of CASI Pharmaceuticals stock for Q2 2017, down 27% quarter-over-quarter.
- 4 funds opened new CASI Pharmaceuticals positions in Q2 2017 and 2 closed out, a net change of +2 holders.
- The largest CASI Pharmaceuticals buyer in Q2 2017 was Citadel Advisors, an estimated $22K added.
- The largest CASI Pharmaceuticals seller in Q2 2017 was Vanguard Group, an estimated $62K sold.
Based on aggregated 13F filings for Q2 2017.